US Drug Price Policy Could Drive Up Costs in Europe and Israel
Translated & summarized from Cursorinfo by baba
The US administration's push to lower drug prices is prompting pharmaceutical companies to seek higher prices in Europe, potentially increasing costs for European nations and indirectly affecting Israel. While the US has significantly higher drug costs, European countries are adopting varied strategies to manage price pressures. Israel, currently benefiting from controlled prices, faces the risk of increased medication expenses if European markets concede to higher purchasing prices.
The story in 6 lines · by baba
- US drug price policies may cause European pharmaceutical costs to rise, impacting Israel.
- Pharmaceutical companies are demanding higher prices from European governments to offset US revenue pressures.
- The US spends significantly more on prescription drugs than European countries.
- European nations like the UK, Germany, and France are implementing different strategies to control drug costs.
- Israel's drug prices could increase if European countries agree to higher purchasing prices.
- Aging populations and budget deficits strain European countries' ability to manage rising healthcare costs.
The US administration's aggressive stance on lowering drug prices, spearheaded by the Trump administration, is creating ripple effects that could lead to higher medication costs in Europe and indirectly impact Israel. Washington's strategy includes tough negotiations with pharmaceutical companies within Medicare and Medicaid, bypassing intermediaries through platforms like TrumpRx, and threatening to peg US prices to those in other countries. These measures are already affecting the profitability of drugmakers in the lucrative US market.
To offset potential revenue losses, pharmaceutical companies are shifting their focus to European governments, demanding higher purchasing prices. The US administration supports this by arguing that other nations should bear a larger share of the research and development costs for new drugs. Currently, original patented drugs in the US are four times more expensive than in Europe, and the US spends 1.6% of its GDP on prescription drugs, significantly more than European countries.
European nations are responding differently to this pressure. The UK has agreed to a 25% increase in net prices for new drugs and plans to double government spending by 2036, partly to avoid US tariffs. Germany, however, has opted for a tougher approach, increasing mandatory manufacturer rebates from 7% to 15.5%, aiming to save €4.1 billion, though this has increased patient co-pays by 50% and raised concerns about new drug availability.
France is attempting a hybrid model, allowing high initial prices for innovative drugs but significantly reducing them later, projecting savings of €3 billion. Despite these efforts, Europe's capacity to absorb further price increases is limited due to budget deficits and aging populations, which will increase healthcare demands.
Major pharmaceutical companies are redirecting billions of dollars in investments to the US, while China is rapidly increasing its share in global clinical research. For Israel, which currently benefits from relatively controlled drug prices due to links to European pricing and strong negotiating power of its health funds, a shift in European pricing policies could lead to higher costs. The long-term challenge for Israel will be balancing cost containment with maintaining market attractiveness for new innovative drugs.